KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Income from Continuing Operations (2017 - 2026)

Aquestive Therapeutics has reported Income from Continuing Operations over the past 9 years, most recently at 31860000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 86.81% year-over-year to 31860000.0; the TTM value through Dec 2025 reached 83784000.0, down 89.83%, while the annual FY2025 figure was 83784000.0, 89.83% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 31860000.0 at Aquestive Therapeutics, down from 15446000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 8068000.0 in Q1 2023 and troughed at 31860000.0 in Q4 2025.
  • A 5-year average of 13037000.0 and a median of 13024000.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: surged 161.03% in 2023 and later crashed 465.55% in 2024.
  • Year by year, Income from Continuing Operations stood at 28945000.0 in 2021, then soared by 57.33% to 12352000.0 in 2022, then soared by 34.33% to 8111000.0 in 2023, then tumbled by 110.27% to 17055000.0 in 2024, then tumbled by 86.81% to 31860000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for AQST at 31860000.0 in Q4 2025, 15446000.0 in Q3 2025, and 13548000.0 in Q2 2025.